Main characteristics of the 118 pediatric patients according to type of VKA and relationship between these characteristics and the VKA maintenance dose by univariate analysis
| . | Warfarin (n = 83) . | Fluindione (n = 35) . | ||
|---|---|---|---|---|
| N (%) or mean ± SD (range) . | P value* . | N (%) or mean ± SD (range) . | P value* . | |
| Mean age, y, ± SD (range) | 8.4 ± 5.6 (3 mo-18 y) | < .0001 | 11.0 ± 3.8 (3 y-18 y) | .4957 |
| Sex, M/F, n | 46/37 | .0082 | 18/17 | .3901 |
| Weight, kg, mean ± SD (range) | 29.5 ± 19.8 (3.5–81.5) | < .0001 | 37.8 ± 17.9 (15.6–76) | .8899 |
| Height, cm, mean ± SD (range) | 120.7 ± 33.4 (50–183) | < .0001 | 139.5 ± 23.6 (92–190) | .5988 |
| Body surface area, m2, mean ± SD (range) | 0.97 ± 0.44 (0.22–1.94) | .0134 | 1.19 ± 0.36 (0.66–1.87) | .8981 |
| Associated medications, mean ± SD (range) | 0.71 ± 1.54 (0–5) | NA | 0.43 ± 1.17 (0–5) | NA |
| Target INR, n (%)† | .1410 | .8574 | ||
| 2.2 | 31 (37) | 7 (20) | ||
| 2.5 | 38 (46) | 11 (31) | ||
| 3.3 | 14 (17) | 17 (49) | ||
| VKORC1 genotype, n (%) | < .0001 | .0363 | ||
| GG | 25 (30) | 16 (46) | ||
| GA | 43 (52) | 14 (40) | ||
| AA | 15 (18) | 5 (14) | ||
| CYP2C9 genotype, n (%)‡ | .1582 | .0613 | ||
| *1/*1 | 53 (64) | 22 (63) | ||
| *1/*x | 25 (30) | 10 (29) | ||
| *x/*x | 5 (6) | 3 (8) | ||
| CYP4F2 genotype, n (%) | .5182 | NA | ||
| CC | 46 (57) | 18 (51) | ||
| CT | 26 (32) | 8 (23) | ||
| TT | 9 (11) | 9 (26) | ||
| . | Warfarin (n = 83) . | Fluindione (n = 35) . | ||
|---|---|---|---|---|
| N (%) or mean ± SD (range) . | P value* . | N (%) or mean ± SD (range) . | P value* . | |
| Mean age, y, ± SD (range) | 8.4 ± 5.6 (3 mo-18 y) | < .0001 | 11.0 ± 3.8 (3 y-18 y) | .4957 |
| Sex, M/F, n | 46/37 | .0082 | 18/17 | .3901 |
| Weight, kg, mean ± SD (range) | 29.5 ± 19.8 (3.5–81.5) | < .0001 | 37.8 ± 17.9 (15.6–76) | .8899 |
| Height, cm, mean ± SD (range) | 120.7 ± 33.4 (50–183) | < .0001 | 139.5 ± 23.6 (92–190) | .5988 |
| Body surface area, m2, mean ± SD (range) | 0.97 ± 0.44 (0.22–1.94) | .0134 | 1.19 ± 0.36 (0.66–1.87) | .8981 |
| Associated medications, mean ± SD (range) | 0.71 ± 1.54 (0–5) | NA | 0.43 ± 1.17 (0–5) | NA |
| Target INR, n (%)† | .1410 | .8574 | ||
| 2.2 | 31 (37) | 7 (20) | ||
| 2.5 | 38 (46) | 11 (31) | ||
| 3.3 | 14 (17) | 17 (49) | ||
| VKORC1 genotype, n (%) | < .0001 | .0363 | ||
| GG | 25 (30) | 16 (46) | ||
| GA | 43 (52) | 14 (40) | ||
| AA | 15 (18) | 5 (14) | ||
| CYP2C9 genotype, n (%)‡ | .1582 | .0613 | ||
| *1/*1 | 53 (64) | 22 (63) | ||
| *1/*x | 25 (30) | 10 (29) | ||
| *x/*x | 5 (6) | 3 (8) | ||
| CYP4F2 genotype, n (%) | .5182 | NA | ||
| CC | 46 (57) | 18 (51) | ||
| CT | 26 (32) | 8 (23) | ||
| TT | 9 (11) | 9 (26) | ||
By univariate analysis: association with the maintenance dose. Parameters with P values in bold were entered in the multivariate model.
Target INR was 2.2 in patients with total cavopulmonary connection; 2.5 in those with aortic valve replacement, dilated cardiomyopathy, coronary aneurysms after Kawasaki disease, or extracardiac diseases; and 3.3 in those with mitral valve replacement.
CYP2C9 genotype: *1/*1, wild-type homozygotes; *1/*x: CYP2C9*2 or CYP2C9*3 heterozygotes; and *x/*x: CYP2C9*2 or CYP2C9*3 homozygotes or compound heterozygotes.
NA indicates not applicable.